{"success":true,"data":{"pressRelease":{"id":"128097","rtpr_id":"nGNX9MYLQD","ticker":"TVRD","exchange":"NASDAQ","all_tickers":["TVRD"],"title":"Tvardi Therapeutics to Participate in Upcoming Investor Events","author":"Globe Newswire","published_at":"2026-08-26T12:00:01.013Z","article_body":"HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc.\n(“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company\nfocused on the development of novel, oral, small molecule therapies targeting\nSTAT3 to treat inflammatory and proliferative diseases, today announced that\nmanagement will participate in the following upcoming investor events:\n\nWells Fargo 21(st) Annual Healthcare Conference\nFormat: 1-on-1 Meetings\nDate: Wednesday, September 9, 2026\nLocation: Boston, MA\n\n2026 Cantor Global Healthcare Conference\nFormat: Fireside Chat and 1-on-1 Meetings\nDate: Thursday, September 10, 2026\nTime: 10:55 AM ET\nLocation: New York, NY\n\nH.C. Wainwright 28(th) Annual Global Investment Conference\nFormat: Company Presentation and 1-on-1 Meetings\nDate: Monday, September 14, 2026\nTime: 4:30 PM ET\nLocation: New York, NY\n\nThe corporate presentation and H.C. Wainwright webcast will be accessible on\nTvardi Investors' website\n(https://www.globenewswire.com/Tracker?data=eU3TfeJHAcTVRw-R3NWv7BC0gpq3utstlGVAwNvhx82gS5p5dUUf7CtHKcwY02qSUbiJjldwJtPDK58MXaEKa40oNMC_5e6a_QUhO-0j4H4cPX27WGMVL5rq3Jw9tZEXePaS3ivKzxNDj_BD-wxYU5fnsQhhn6bnz44o8UA_lP5wE1g1ZjTItYPuo48_FTWR_0yLKEoujKCOAW3XCJJBIk0JhCnVnCbNSy-Tkozqv0ebmZ-tMib3ZPODNx63jJRWegnFl2OT6DjxHixQLExrawSyZjfVKmLiNNlNyrnUhomRJLqjJG4i5oyJYPGadBu13zc2vgmBRtuKeaPCU4yQjQ==).\nA replay of the webcast will be available for approximately 90 days following\nthe conference.\n\nAbout Tvardi Therapeutics\n\nTvardi is a clinical-stage biopharmaceutical company focused on the\ndevelopment of novel, oral, small molecule therapies targeting STAT3 to treat\ninflammatory and proliferative diseases with significant unmet need. STAT3 is\na central mediator across critical signaling pathways that drive immune\ndysregulation, inflammation and proliferation, survival and, is also\npositioned at the intersection of many signaling pathways integral to the\nsurvival and immune evasion of cancer cells. TTI-109 is an oral prodrug of\nTTI-101, Tvardi's first STAT3 inhibitor, designed to deliver equivalent\nexposure with improved tolerability. In a completed Phase 1 healthy volunteer\nstudy, TTI-109 demonstrated pharmacodynamic STAT3 target engagement, with\nreductions across disease-relevant cellular and humoral immune cell\npopulations. The Company has selected ulcerative colitis as the initial\nindication for TTI-109 and plans to initiate a clinical trial pending IND\nclearance and the availability of additional funding. Tvardi is also\nconducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma\n(NCT05440708\n(https://www.globenewswire.com/Tracker?data=Wz4VbbPhmvIeLbz3oITs8l2j8CjZWQ_fV0qp699LdJI2HIiVtMrqxfHLZLo1sG-GB-xg_5AM7CjTcmbxJPVYkzpqJDVvVeQaGEKHBgDg8FybO0PDrde9Kvb852rYdbRIONevCh2dhLSufsJR7haEbzbyoeErYaGhW1B0EOT4qeoOTu9FT8aQvDPWDwv6ON0Bap2S-nffQj4CMcI3vObqGWB6mnsykTMojes_6wejPbilzjAGg56AhW4rMQGE7kOE_-lHQLktK3LRwWphrR_2OE8Sl4vcS7SiVJWFdE0P3AE=)).\nTo learn more, please visit tvarditherapeutics.com\n(https://www.globenewswire.com/Tracker?data=FpAfXz0mf42LQ2E8vSPVP5byltfflmBOmqnGYCKUBcG5gqjUBYiOoykpNiKe93ZUtymNxZ3Hbzm5osZ-Wd3Dy-VXiqSq1Xl7OtL-RR8D4qQuUZIxyj5VxNYR8aNrWRhk68dDYIew6hYE61Y42EkHr-5omoHysSjdFKSAcMBQrb45gojOCzszn305R8nJKJW8J5i_hyCQD4ViYqKkCC3VZZ3Pgvk4i_ZUnfciSlgi7FuMY7UUy1QjDi3g-2lZ6Lr44ZWoghPp7uYv4VrFMLKFZJtMKjGdIDOIkSfO2DPT--w=)\nor follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=-6be30SKeoNNAEqMi0GQfsdVKoiZ8YPp8IGJlrzvtfA2Ndbgx930chhJ-mtPGKcQPPFVj40KRj7ieakJjmr_VkTlNpMe7IsaRfZiAVuK_Vs67NYBTqEtgxaFXJ8uNE5999yXMlmd9yurg0I5lrcxL0q_ON4Ia48u-ci28knJZ9s7FUMpsqj5R5uQjcbJNOb-Wxp6E4nkMYWIW3c6wc6iahJnIvBS15D2hrkWFTzo3cNSXq7u2HbhzwyH8rkPs2lFi1n_xaXLlwgA-O4R_a_YdQ==)and\nX (Twitter)\n(https://www.globenewswire.com/Tracker?data=Zfm43MiMxRi1uBvCHn1UE07eJUOc4v667pbPeL6FDmQ0yi0PNEVHldYxNuooNReAlqjxAXg_rlhlLtuYn5peuFsk6i_EZHB7XNT8U53p8RtU_5WhW6-IZ42rc17Cz_2jV6doQh4f0fACzgulfjBY-x0yvQv8ADWa4b0V7GnLdkawq0WzvcoKzK5_XFRA5X4a1DcSR5JqV9QlPzzR0wRbKRN8nejnb-Y0HNa7-WkCmXdfvRXv68oxw_grlztZZW_2).\n\nContacts:\n\nFor Tvardi:\nTvardi Investor Relations\nir@tvardi.com\n\nPJ Kelleher\nLifeSci Advisors\n617-430-7579\npkelleher@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/65859e40-e7db-474e-b604-78033b160f6b)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9MYLQD","title":"Tvardi Therapeutics to Participate in Upcoming Investor Events","author":"Globe Newswire","ticker":"TVRD","created":"2026-08-26T12:00:01.013Z","tickers":["TVRD"],"exchange":"NASDAQ","article_body":"HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc.\n(“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company\nfocused on the development of novel, oral, small molecule therapies targeting\nSTAT3 to treat inflammatory and proliferative diseases, today announced that\nmanagement will participate in the following upcoming investor events:\n\nWells Fargo 21(st) Annual Healthcare Conference\nFormat: 1-on-1 Meetings\nDate: Wednesday, September 9, 2026\nLocation: Boston, MA\n\n2026 Cantor Global Healthcare Conference\nFormat: Fireside Chat and 1-on-1 Meetings\nDate: Thursday, September 10, 2026\nTime: 10:55 AM ET\nLocation: New York, NY\n\nH.C. Wainwright 28(th) Annual Global Investment Conference\nFormat: Company Presentation and 1-on-1 Meetings\nDate: Monday, September 14, 2026\nTime: 4:30 PM ET\nLocation: New York, NY\n\nThe corporate presentation and H.C. Wainwright webcast will be accessible on\nTvardi Investors' website\n(https://www.globenewswire.com/Tracker?data=eU3TfeJHAcTVRw-R3NWv7BC0gpq3utstlGVAwNvhx82gS5p5dUUf7CtHKcwY02qSUbiJjldwJtPDK58MXaEKa40oNMC_5e6a_QUhO-0j4H4cPX27WGMVL5rq3Jw9tZEXePaS3ivKzxNDj_BD-wxYU5fnsQhhn6bnz44o8UA_lP5wE1g1ZjTItYPuo48_FTWR_0yLKEoujKCOAW3XCJJBIk0JhCnVnCbNSy-Tkozqv0ebmZ-tMib3ZPODNx63jJRWegnFl2OT6DjxHixQLExrawSyZjfVKmLiNNlNyrnUhomRJLqjJG4i5oyJYPGadBu13zc2vgmBRtuKeaPCU4yQjQ==).\nA replay of the webcast will be available for approximately 90 days following\nthe conference.\n\nAbout Tvardi Therapeutics\n\nTvardi is a clinical-stage biopharmaceutical company focused on the\ndevelopment of novel, oral, small molecule therapies targeting STAT3 to treat\ninflammatory and proliferative diseases with significant unmet need. STAT3 is\na central mediator across critical signaling pathways that drive immune\ndysregulation, inflammation and proliferation, survival and, is also\npositioned at the intersection of many signaling pathways integral to the\nsurvival and immune evasion of cancer cells. TTI-109 is an oral prodrug of\nTTI-101, Tvardi's first STAT3 inhibitor, designed to deliver equivalent\nexposure with improved tolerability. In a completed Phase 1 healthy volunteer\nstudy, TTI-109 demonstrated pharmacodynamic STAT3 target engagement, with\nreductions across disease-relevant cellular and humoral immune cell\npopulations. The Company has selected ulcerative colitis as the initial\nindication for TTI-109 and plans to initiate a clinical trial pending IND\nclearance and the availability of additional funding. Tvardi is also\nconducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma\n(NCT05440708\n(https://www.globenewswire.com/Tracker?data=Wz4VbbPhmvIeLbz3oITs8l2j8CjZWQ_fV0qp699LdJI2HIiVtMrqxfHLZLo1sG-GB-xg_5AM7CjTcmbxJPVYkzpqJDVvVeQaGEKHBgDg8FybO0PDrde9Kvb852rYdbRIONevCh2dhLSufsJR7haEbzbyoeErYaGhW1B0EOT4qeoOTu9FT8aQvDPWDwv6ON0Bap2S-nffQj4CMcI3vObqGWB6mnsykTMojes_6wejPbilzjAGg56AhW4rMQGE7kOE_-lHQLktK3LRwWphrR_2OE8Sl4vcS7SiVJWFdE0P3AE=)).\nTo learn more, please visit tvarditherapeutics.com\n(https://www.globenewswire.com/Tracker?data=FpAfXz0mf42LQ2E8vSPVP5byltfflmBOmqnGYCKUBcG5gqjUBYiOoykpNiKe93ZUtymNxZ3Hbzm5osZ-Wd3Dy-VXiqSq1Xl7OtL-RR8D4qQuUZIxyj5VxNYR8aNrWRhk68dDYIew6hYE61Y42EkHr-5omoHysSjdFKSAcMBQrb45gojOCzszn305R8nJKJW8J5i_hyCQD4ViYqKkCC3VZZ3Pgvk4i_ZUnfciSlgi7FuMY7UUy1QjDi3g-2lZ6Lr44ZWoghPp7uYv4VrFMLKFZJtMKjGdIDOIkSfO2DPT--w=)\nor follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=-6be30SKeoNNAEqMi0GQfsdVKoiZ8YPp8IGJlrzvtfA2Ndbgx930chhJ-mtPGKcQPPFVj40KRj7ieakJjmr_VkTlNpMe7IsaRfZiAVuK_Vs67NYBTqEtgxaFXJ8uNE5999yXMlmd9yurg0I5lrcxL0q_ON4Ia48u-ci28knJZ9s7FUMpsqj5R5uQjcbJNOb-Wxp6E4nkMYWIW3c6wc6iahJnIvBS15D2hrkWFTzo3cNSXq7u2HbhzwyH8rkPs2lFi1n_xaXLlwgA-O4R_a_YdQ==)and\nX (Twitter)\n(https://www.globenewswire.com/Tracker?data=Zfm43MiMxRi1uBvCHn1UE07eJUOc4v667pbPeL6FDmQ0yi0PNEVHldYxNuooNReAlqjxAXg_rlhlLtuYn5peuFsk6i_EZHB7XNT8U53p8RtU_5WhW6-IZ42rc17Cz_2jV6doQh4f0fACzgulfjBY-x0yvQv8ADWa4b0V7GnLdkawq0WzvcoKzK5_XFRA5X4a1DcSR5JqV9QlPzzR0wRbKRN8nejnb-Y0HNa7-WkCmXdfvRXv68oxw_grlztZZW_2).\n\nContacts:\n\nFor Tvardi:\nTvardi Investor Relations\nir@tvardi.com\n\nPJ Kelleher\nLifeSci Advisors\n617-430-7579\npkelleher@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/65859e40-e7db-474e-b604-78033b160f6b)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-26T12:00:01.060068252Z","server_sent_at_ms":1787745601060},"received_at":"2026-08-26T12:00:01.110Z","source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351266/0/en/tvardi-therapeutics-to-participate-in-upcoming-investor-events.html"},"analysis":{"id":"117012","press_release_id":"128097","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["plans to initiate clinical trial pending 'availability of additional funding'"],"eventType":"other","narrative":"Tvardi Therapeutics management will participate in three investor conferences in September, including events hosted by Wells Fargo, Cantor Global, and H.C. Wainwright.\n\nA corporate presentation and webcast for the H.C. Wainwright conference will be accessible on the company's website, with a replay available for 90 days.\n\nThe company is a clinical-stage biopharma focused on STAT3 inhibitors, with TTI-109 planned for ulcerative colitis and TTI-101 currently in a Phase 1b/2 trial for hepatocellular carcinoma.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference attendance schedule."},"keyFigures":{"customDimensions":{"nct_id":"NCT05440708"}},"quotedText":"","namedEntities":{"people":[],"products":["TTI-109","TTI-101"],"companies":[{"name":"Tvardi Therapeutics, Inc.","ticker":"TVRD"},{"name":"Wells Fargo","relationship":"conference host"},{"name":"Cantor Fitzgerald","relationship":"conference host"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"LifeSci Advisors","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of management participation in investor conferences. No new clinical, financial, or regulatory data was disclosed."},"tickerRelevance":{"others":[],"primary":"TVRD"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"investor_conference"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Tvardi Therapeutics management will participate in three investor conferences in September, including events hosted by Wells Fargo, Cantor Global, and H.C. Wainwright.\n\nA corporate presentation and webcast for the H.C. Wainwright conference will be accessible on the company's website, with a replay available for 90 days.\n\nThe company is a clinical-stage biopharma focused on STAT3 inhibitors, with TTI-109 planned for ulcerative colitis and TTI-101 currently in a Phase 1b/2 trial for hepatocellular carcinoma.","key_figures":{"customDimensions":{"nct_id":"NCT05440708"}},"named_entities":{"people":[],"products":["TTI-109","TTI-101"],"companies":[{"name":"Tvardi Therapeutics, Inc.","ticker":"TVRD"},{"name":"Wells Fargo","relationship":"conference host"},{"name":"Cantor Fitzgerald","relationship":"conference host"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"LifeSci Advisors","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-26T12:35:04.755Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"micro-cap","eventGravity":"investor_conference"}},"durationMs":121392,"modelName":"glm-4.7"}}